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Abstract
3D porous scaffolds based on agarose and nanocrystalline apatite, two structural components that act as a 
temporary mineralized extracellular matrix, were prepared by the GELPOR3D method. This shaping technology 
allows the introduction of thermally-labile molecules within the scaffolds during the fabrication procedure. An 
angiogenic protein, Vascular Endothelial Growth Factor, and an antibiotic, cephalexin, loaded in mesoporous 
silica nanoparticles, were included to design multifunctional scaffolds for bone reconstruction. The dual release 
of both molecules showed a marked increase in the number of blood vessels on embryonic day 14 in chicken 
embryos grown ex ovo, while, at the same time providing an antibiotic local concentration capable of inhibiting 
Staphylococcus aureus bacterial growth. In this sense, different release patterns, monitored by UV-spectroscopy, 
could be tailored as a function of the cephalexin loading strategy, either releasing all the loaded cephalexin in the 
first 4 h or less than 50 % after 24 h. The scaffold surface was characterized by a high hydrophilicity, with contact 
angles between 50 and 63º, which enabled the adhesion and proliferation of preosteoblastic cells.




Bone tissue has a great regeneration capacity that enables the recovery of its structure and funcion after fracture, 
even without the formation of scar tissue. However, as an individual ages, this regeneration capacity is gradually 
compromised [1–3], and people older than 85 years are at least 10 times more likely to suffer a bone fracture than 
people in the 60-65 year range [1]. As a consecuence of the remarcable increase in life expectancy in recent 
decades, pathologies related to bone fragility entail great social and economic importance. Healthcare costs for 
osteoporosis in women older than 75 years are nearly 20 times greater than those for women in the range of 45 
to 54 years [4]. Bone fractures also constitute an important cause of morbidity, with around half of those who 
survive one year after fracture becoming totally or partially dependent [5], and musculoskeletal disorders as a 
whole being the second cause for disability worldwide [6]. In this context, surgical replacement of bone tissue has 
become a common and necessary procedure (being estimated that around 7 million people lived with total hip or 
knee replacements in 2010 in the USA [7]), with different alternatives being employed in the clinical practice 
regarding the source of the bone replacement material. While autografts (employing bone tissue from the own 
patient) is generally recognised as the gold standard, the limited amount of bone tissue susceptible of being 
employed for this purpose and the invasiveness of the procedure severely restrain its use in the clinical setting. 
On the other hand, allografts from different patients and especially xenografts from other species present safety 
concerns related to the host´s immune response and possibility of infectious diseases. Hence, the search for 
synthetic materials capable of mimicking bone tissue as closely as possible has become a tremendously active 
area of research in recent years [8–14]. 
Bone is a complex tissue for which the spatial disposition of its components in a porous structure is critical for 
its performace. Therefore, these synthetic materials must be assembled in scaffolds that must fulfill many 
requirements related to their biocompatibility and biodegradability, a 3D interconnected hierarchical porous 
architecture and mechanical performance [15,16]. Many different materials have been evaluated in recent years 
including metals (titanium, magnesium...), ceramics (calcium phosphates, bioactive glasses...), polymers 
(collagen, chitosan, polycaprolactone, poylactic acid...) or in combination, composites [12,14,17–21]. Besides the 
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mentioned requirements for the materials in terms of chemical properties and architecture, the recreation of a 
favourable microenvironment when repairing a bone defect requires the release of biologically-active molecules 
at the site for a determined period of time, while also ensuring the retention of their biological activity over this 
same timeframe. In this sense, scaffolds designed as platforms for the release of multiple drugs/biomolecules are 
considered as a key strategy for tissue engineering [22–24]. 
The requirement of proper vascularization of the implanted biomaterials to warrant their optimal behavior 
involves the development of porous scaffolds. The inclusion of pro-angiogenic factors (such as Vascular 
Endothelial Growth Factor, VEGF) can induce the succesful colonization of such porous materials by blood 
vessels, surpassing this first bottleneck of regenerative medicine [25,26]. In addittion, this growth factor has 
proven to enhance both endochondral ossification and intermembranous bone formation while, at the same time, 
increase stem cell recruitment [26]. 
On the other hand, bone defect-related infections (highlighting staphylococci infections) [27] constitute a 
severe burden for bone regeneration, and drastically reduce the quality of life of affected patients. Thus, it is 
required to develop bone regeneration scaffolds that can simultaneously avoid the appearance of infection. While 
the inclusion of antibiotic drugs within these materials has shown promising results [28–33], difficulties in achieving 
a proper control over drug release in these systems stands as an unresolved issue. Nanoparticles have been 
proposed and extensively studied to control the release of different types of drugs [34–36]. The inclusion of 
nanoparticles within the scaffolds is a powerful tool that ensures a targeted delivery, biomolecule preservation 
and enables different release kinetics that each of the molecules included require for its optimal benefitial effect 
[37–39]. In this context, mesoporous silica nanoparticles show promising characteristics as drug carriers, such as 
their high loading capacity, physicochemical stability and excellent biocompatibility [40,41]. One of the main 
advantages of the inclusion of these loaded nanoparticles into scaffolds is derived from the local delivery into the 




The aim of this study was the fabrication of a novel scaffold tailored to improve its resistance against infection 
and promote its vacularization thus facilitating its final performance in bone regeneration. This task requires a 
biodegradable scaffold that acts as a temporary extracellular matrix where cells can migrate to and proliferate 
thus favouring tissue regeneration.The 3D porous scaffolds are composed of apatite and agarose, as structural 
components, plus cephalexin-loaded mesoporous silica nanoparticles and VEGF. The morphological 
characteristics, culture with preosteoblast cells, drug release behavior, antibacterial effect against Staphylococcus 
aureus, and angiogenesis behaviour in chicken embryos grown ex ovo were here investigated. 
2. Materials and methods 
2.1. Synthesis and characterization of materials. 
Mesoporous Silica Nanoparticles. Silica nanoparticles (NP) were synthesized by a modified Stöber method from 
tetraethyl orthosilicate in the presence of cetyltrimethylammonium bromide as structure-directing agent [42,43]. 
The synthesis was performed under basic and very dilute conditions and at T= 80 ºC under stirring for 2 h, as 
described elsewhere [43]. The surfactant template was removed by ion exchange using an extracting solution of 
NH4NO3 (10 mg/mL) in ethanol (95 %). The particles were suspended in that medium and magnetically stirred at 
75 ºC overnight. Subsequently, they were centrifuged and washed three times with deionized water and ethanol. 
The product was dried under vacuum at 25 ºC. Mesoporous nanoparticles were loaded with cephalexin by 
impregnation method [44,45]. Drug loading was performed by dispersing 100 mg nanoparticles in 25 mL of an 
aqueous solution of cephalexin (8 mg/mL), and magnetically stirring them 24 h at room temperature. After this 
time, loaded nanoparticles (CxNP) were centrifuged and washed with water 3 times to remove the cargo adsorbed 
on the external surface. Finally, the sample was dried under vacuum at 25 °C. 
Nanocrystalline Hydroxycarbonateapatite powder. Nanocrystalline Hydroxycarbonateapatite (nHCA) with similar 
characteristics to the bone apatite was prepared by aqueous precipitation reaction at pH = 9.2 (NH4OH solution) 
and 37ºC according to the method reported elsewhere [46,47]. To summarize, 1 L of 1 M solution of 
Ca(NO3)2·4H2O and 1 L of 0.6 M (NH4)2HPO4 and 0.3 M (NH4)2CO3 were prepared. Both solutions were 
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simultaneously added into a reactor at a flow rate of 30 mL/min by using a peristaltic pump (MINIPULS® 3 from 
Gilson). After the addition, the solution was stirred during 10 min at 2000 rpm. The white solid precipitated was 
filtered and washed several times with hot water and then dried overnight by freeze-drying. Afterwards, the powder 
was sieved and the fraction of particles with sizes lower than 60 m was used for the scaffold fabrication. 
Fabrication of Scaffolds. Three-dimensional macroporous agarose/nHCA scaffolds, in a 50/50 ratio, and 
containing VEGF and cephalexin, were fabricated using a simple shaping process named GELPOR3D [48–50] 
(Fig. 1): Agarose powder (Sigma–Aldrich, Steinheim, Germany, for routine use), was suspended in deionized 
water (3.5 % w/v) and heated to 90 ºC with continuous stirring; once a translucent sol was achieved, temperature 
was gradually decreased to 45 ºC and then, the ceramic powder (nHCA) was added. In this step, cephalexin was 
also added to the suspension in two ways obtaining two series of scaffolds: (a) free in solution (S-CxF); (b) 
encapsulated in nanoparticles (S-CxNP). In both cases, the amount of cephalexin included into the scaffolds was 
8 mg cephalexin/g nHCA. The angiogenic factor was incorporated by adding 11.5 g of VEGF/g nHCA, previously 
dissolved in phosphate buffered saline solution (100 g VEGF/mL PBS), to the above mentioned suspension. 
The amount of VEGF selected was chosen so that the final dose of VEGF per sample tested on the chick embryos 
was 0.5 µg, same dose as we had found in the literature for chick embryo angiogenesis experiments [51–53]. 
The resulting slurry was poured into a designed cubic mold that provides the 3D macroporosity (Fig. 1). After five 
minutes at room temperature complete consolidation of the bodies was reached. After withdrawal of the designed 
mold, the freshly prepared scaffolds could be easily cut and shaped. 
Characterization techniques. The materials were analysed by X-ray diffraction (XRD) in a Philips X-Pert MPD 
diffractometer equipped with Cu K radiation. Thermogravimetry and Differential Temperature Analysis 
(TGA/DTA) were performed in a Perkin Elmer Pyris Diamond TG/DTA analyser, with 5 oC/min heating ramps, 
from room temperature to 600 ºC. Fourier Transform Infrared (FTIR) spectra were obtained in a Nicolet (Thermo 
Fisher Scientific) Nexus spectrometer equipped with a Smart Golden Gate ATR accessory. Surface morphology 
was analysed by Transmission Electron Microscopy (TEM) in a JEOL JEM 2100 instrument operated at 200 kV 
and by Scanning Electron Microscopy (SEM) in a JEOL JSM6335F Electron microscope equipped with an Energy-
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dispersive-X-ray analysis (EDS) detector. N2 adsorption was carried out on a Micromeritics ASAP 2020 
instrument: surface area was obtained by applying the BET method to the isotherm and the pore size distribution 
was determined by the BJH method from the desorption branch of the isotherm. The mesopore diameter was 
determined from the maximum of the pore size distribution curve. The zeta potential and hydrodynamic size of 
nanoparticles were measured in aqueous solution by means of a Zetasizer Nano ZS (Malvern Instruments) 
equipped with a 633 nm “red” laser. Static contact angle measurements were carried out on bulk samples using 
a contact angle measuring instrument (CAM200, KSV Instruments, Finland).
2.2. In vitro studies.
Cephalexin release study: In vitro release assays were performed by soaking nanoparticles or scaffolds in 
phosphate buffered saline solution (PBS 1x) at 37 °C and pH 7.4 under mechanical oscillations. The time-
dependent cephalexin release was followed by UV spectroscopy [54], using an UNICAM UV500 
spectrophotometer, since the cephalexin is UV-active due to the aromatic rings. Absorbance values were taken 
at a wavelength of 260 nm. Cephalexin solutions at concentrations of 2.5-50 µg/mL were used as standards. 
Experiments were repeated three times and results were expressed as means ± standard deviations. 
Cytotoxicity assay and Cell proliferation: Prior to cell culture experiments, the prepared scaffolds were immersed 
in complete culture medium (Dulbecco´s Modified Eagle´s Medium (DMEM) with 10% Fetal bovine serum (FBS), 
1 % glutamine and 1 % Pen-Strep) and stabilized at 37 ºC overnight. Then, 20000 MC3T3-E1 preosteoblast cells 
were seeded inside the prepared scaffolds and cultured for other 3 days in an incubator at 37 ºC in a humidified 
atmosphere of 5 % CO2. Then, the Alamar Blue cell proliferation/viability assay (Promega, Spain) was performed 
following the manufacturer´s instructions [55]. Experiments were repeated three times and results were expressed 
as means ± standard deviations. Data analysis: The uncertainty about the normality of the obtained data 
precluded the use of parametric statistical tests, while non-parametric tests lacked the necessary statistical power 
with the evaluated number of repeats (n = 3). According to the International standard ISO 10993-5 regarding tests 
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for in vitro cytotoxicity of medical devices (which indicates a minimum number of repeats of n = 3, as used here), 
materials leading to a cell viability result above 70 % of the control were considered as non-cytotoxic.
In vitro bacterial growth inhibition: Agar disk diffusion tests were used to examine the antibacterial effect of 
scaffolds loading with Cephalexin [19].  Prior to the bacterial test, the samples were sterilized by UV-light radiation 
during 10 min in both sides. To perform the inhibition test, disks of 16 x 4 mm were used, prepared from slurries 
with and without cephalexin as above described. The surface of solid agar in Petri dishes was inoculated with a 
suspension of Staphylococcus Aureus bacterial culture with a cell concentration of 1.3 x 1010 bacteria/mL. After 
that, the samples were placed on the agar plates followed by incubation at 37 ºC for 24 h. Then, the bacterial 
inhibition zone size was measured.
2.3 Ex ovo studies.
The chorioallantoic membrane (CAM) of chicken embryos grown ex ovo was employed as a model to evaluate 
the angiogenic potential of the samples prepared. Fertilized eggs were incubated from embryonic day (ED)-1 to 
ED-4 in a hatcher with rotation at 38 °C at 60 % humidity. On ED-4, the embryos were de-shelled following an 
established method [56] with the help of a Dremel drilling tool and transferred into sterilized weighing boats. A 
sterile square petri dish was used to cover the embryos, which were then transferred into a static humidified 
incubator at 38 °C, 60 % humidity and 0.5 % CO2. Scaffolds with/without VEGF were placed on top of the CAM 
of chicken embryos on ED-10. On ED-14, the blood vessels around the samples were evaluated under a 
stereomicroscope and photographed using a 4x objective. 
3.  Results and Discussion
3.1. Mesoporous Silica Nanoparticles.
The main characteristics of SiO2-nanoparticles synthesized to encapsulate cephalexin are collected in Figures 2 
and S1 (Supporting information). The prepared materials were constituted by nanoparticles with a round-shape 
morphology and a size around 100 nm as it can be observed in the TEM image (Fig. 2A). The obtained nitrogen 
adsorption isotherms were type IV, with characteristic surface areas (1026 m2/g) and cylindrical parallel pores 
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(pore diameter of 2.9 nm) for this type of NPs (Fig. 2B). The surface Zeta potential of the nanoparticles was -
30.4mV with a hydrodynamic particle diameter of ca. 140 nm (Fig. S1a). Typical XRD patterns of MCM-41 type 
materials were observed, with the three characteristic maxima (100), (110) and (200), confirming the 2D 
hexagonal order of the mesopores arrangement (Fig. S1b). The presence of cephalexin in the nanoparticles was 
confirmed by FTIR spectroscopy (Fig. S1c) by the appearance of new bands in the 1600-1700 cm-1 region in the 
corresponding FTIR spectrum [57]. The incorporation of cephalexin into the pores provoked a decrease in the 
BET surface area (Figure 2B) of the nanoparticles (700 m2/g) although the order of the mesoporous channels 
was not affected (Fig. S1b).
Nanoparticles loaded with cephalexin were immersed in a buffered aqueous solution (pH= 7.4) at 37 ºC to 
study the release of the drug to the medium. Fig. 3 shows the release profile as a function of immersion time. 
Cephalexin release data could be fitted to a first-order kinetic model (equation 1) by using GraphPad Prism 
software:  
            Y = A(1-e-kt)          Equation 1
being Y the percentage of cephalexin released at time t, A the maximum amount of cephalexin released (in 
percentage), and k, the release kinetic constant [58,59]. The drug release exhibits two steps: a fast delivery (burst 
effect) was observed over the first 5 hours, followed by a slow release at longer times. The parameters of the 
kinetic fitting are shown in Figure 3. In the FTIR spectra after drug release experiments (Fig. S1c) vibrational bands 
corresponding to cephalexin were not appreciated. Consequently, the maximum amount of drug released from 
the silica nanoparticles, around 2 %, must be similar to the cephalexin adsorbed into the mesopores of the 
nanoparticles. 
3.2. Multifunctional agarose/apatite scaffolds.
The structural basis of these multifunctional scaffolds was designed considering the mineralized water-rich matrix 
and highly vascularized architecture of the bone tissue to be repaired. These scaffolds contained nHCA and 
agarose as the majority structural components which would contribute to bone growth. The inorganic component, 
nHCA, synthesized by a precipitation method, showed similar characteristics to the bone apatite [60]: XRD 
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patterns were characteristic of a nanocrystalline apatite phase, FTIR spectrum showed bands corresponding to 
PO43-, CO32- and OH- groups and SEM micrographs showed the nanometric size of nHCA particles (Fig. S2). 
These apatite crystals were embedded in an agarose matrix, a natural polysaccharide that acted as a gelling 
agent and with hydrogel behaviour due to the hydrophilic nature of its chains [61]. Both structural scaffold 
components can be easily degraded thus facilitating its progressive substitution by neo-formed tissue. In an 
aqueous medium the hybrid scaffold would behave like a reinforced hydrogel and could absorb water within its 
structure, swell without destruction, and maintain its overall structure in an environment that resembled the 
extracellular matrix [62,63].
Cephalexin, a β-lactamic antibiotic from the group of cephalosporins, was chosen due to its effectiveness 
against Gram-positive bacteria [57]. Traditionally, drugs have been introduced into scaffolds by an 
immersion/impregnation process being the drug adsorption dependent on, among others, the specific surface 
area of the scaffold material. However, taking into account that the shaping method employed to prepare the 
scaffolds, GELPOR3D, was developed at physiological temperatures, bioactive molecules, most of them 
thermally-labile, could be added during the scaffold fabrication process. The introduction of cephalexin into the 
agarose/nHCA suspension, either dissolved in an aqueous solution (S-CxF) or encapsulated into silica 
nanoparticles (S-CxNP, 20 % weight of NP), seemed not to affect neither the gelation time/process nor the 
capacity to easily shape the samples. Moreover, the addition the VEGF to the scaffolds did not change these 
features either.
The scaffolds were designed with a hierarchical porosity that could contribute to new bone ingrowth. Figure 4 
illustrates an image of the composite fabricated scaffold containing SiO2-nanoparticles (Fig. 4A) as well as SEM 
images (Fig. 4B and 4C). The composite scaffold exhibited a 3D interconnected porous network, which was 
constituted by macropores around 800 µm, a size slightly smaller than the filaments forming the mold. Besides 
the creation of this network of interconnected “giant” pores, this method allowed to tailor this porosity percentage, 
calculated to be a 30 %, as a function of the filament size and the grid pattern [49]. In addition, these scaffolds 
showed additional porosity which ranged between 100 and 50 nm that can be attributed to the space left between 
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the nHCA particles. This hierarchical porosity distribution results critical, on one side, to facilitate an adequate 
vascularization thanks to the macropores, while, on the other the interparticular porosity ensures the permeation 
and fluid migration throughout the whole scaffold volume. In fact, this macroporosity facilitates cell intrusion and 
the production of extracellular matrix within the scaffold in ectopic implants [64]. A detailed examination at higher 
magnification shows the distribution of the nanoparticles (indicated by arrows in Fig. 4C) embedded within the 
agarose/ceramic hydrogel matrix. 
Figure 5 shows the EDS elemental mapping of calcium, phosphorus and silicon in agarose/nHCA scaffolds 
without and with nanoparticles. These images indicate that the chemical elements were distributed 
homogeneously, that is, the crystals of apatite, as well as the SiO2-nanoparticles, were homogeneously distributed 
throughout the agarose matrix. 
In order to fulfill its purpose as a bone regeneration scaffold, our samples had to enable cell growth on their 
surface. Previous studies had shown that osteoblastic cells adhered to our agarose/nHCA scaffolds, proliferated 
and colonized its surface [63], and these scaffolds are capable of promoting in vivo osteogenesis in ectopic areas 
[64]. Now the aim was to study if this behavior was maintained in presence of the SiO2 nanoparticles. Surface 
hydrophilicity is a commonly used parameter to predict the biological behavior of biomaterials, with hydrophilic 
surfaces being regarded as suitable for cell adhesion and proliferation [19,65]. Therefore, static contact angle 
measurements of the employed compositions were carried out. Non-porous disks having the same composition 
as the studied scaffolds were obtained by pouring the corresponding slurries into Petri dishes and then dried at 
37 ºC overnight. Distilled water (3 L) was added to the different disks by a motor-driven syringe at room 
temperature. Reported data were obtained by averaging the results of three measurements. The results obtained 
(Fig. 6A) show that all the compositions employed to prepare our samples provide a hydrophilic surface (contact 
angle between 50 and 63º, well below 90º). These results indicate that the surface of the prepared materials would 
be suitable for cell growth due to the materials presenting a water contact angle compatible with cell adhesion and 
proliferation. This was further confirmed by seeding MC3T3 preosteoblast cells on the produced scaffolds (with 
and without nanoparticles). Three days later, cell proliferation was evaluated through the Alamar Blue assay (Fig. 
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6B), which showed that cells could grow and proliferate on the prepared scaffolds at the same rate as the control 
culture (cells grown on a culture plate well). These results indicate that the materials were not toxic, and cell 
growth on its surface was not different from cells grown on the cell culture well. All of these results taken together 
show the good biological behavior of the prepared scaffolds, even those containing SiO2 nanoparticles, which 
would enable the growth of bone cells on their surface, a critical step to allow proper bone regeneration in the 
area. 
Considering the dual aim of designing scaffolds to enable bone repair and control infection, we have fabricated 
bone scaffolds loaded with an antibiotic, cephalexin, introduced during the fabrication process. Two types of hybrid 
scaffolds were synthesized: S-CxF, scaffolds containing the structural components and free cephalexin and S-
CxNP, which contained the major components and cephalexin encapsulated into nanoparticles. The release 
profiles of cephalexin from these hybrid scaffolds in the buffered aqueous solution are collected in Figure 7. In 
both cases, the release data were fitted to a first-order kinetic model with an empirical correction factor (δ) 
(Equation 2). 
Y = A(1-e-kt)δ                  Equation 2
where Y, A and k, were described above. The values for δ are comprised between 1 for materials that follow first-
order kinetics, and 0, for materials that release the loaded drug in the very initial time of analysis [66]. Data showed 
in figure 7 indicated that the scaffolds released practically all the loaded cephalexin in the first 4 h when the drug 
was not encapsulated (S-CxF). When the cephalexin was incorporated into the nanoparticles (S-CxNP), although 
a burst release of the drug was observed also at very short times, the release kinetic constant was much lower 
(0.22 h-1 vs 0.68 h-1), and only around 40 % of the drug was released after 24 h. This result indicates the 
achievement of a sustained release profile of the antibiotic cephalexin when the drug was incorporated inside 
mesoporous silica nanoparticles prior to their incorporation into our bone regenerative scaffolds.
Agar disk diffusion test after 24 h (Fig. 8) indicated that only S-CxF scaffolds, which were fabricated with free 
cephalexin, inhibited bacterial growth of Staphylococcus Aureus (outer diameter of the inhibition zone 22.2 mm), 
while the disk with nanoparticles with and without drug (S-CxNP and S-NP, respectively) failed to inhibit bacterial 
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growth. These data indicate, on one hand that the cephalexin did not lose its activity during the scaffold fabrication 
process and on the other, that the drug released from the scaffold containing cephalexin-loaded nanoparticles 
was not enough to achieve the minimum inhibitory concentration needed to inhibit bacterial growth.
According to the results collected in figures 7 and 8, encapsulating cephalexin into NPs was a good approach 
to prolong antibiotic treatment, but due to its slow release kinetic, more than 24 h would be necessary to reach a 
therapeutic concentration in the surrounding environment. Then, a combination of both strategies, delivery of 
cephalexin directly from the scaffold matrix and also incorporated into the nanoparticles, could be a solution in 
clinical practice. Then, a scaffold containing both, cephalexin encapsulated into NP and free antibiotic, S-
Cx(F+NP), (Fig. 9), was fabricated in a similar way to that described above. In this case the amount of CxNP 
included in the scaffold S-Cx(F+NP), was the same as for S-CxNP, and half of that amount was also included in 
its free form (final cephalexin amount was 12 mg of drug/g nHCA). The Agar disk diffusion test as well as the drug 
release profile corresponding to this strategy can be observed in figure 9. The appearance of a bacterial growth 
inhibition zone indicated that, unlike for S-CxNP, the minimum inhibitory concentration was achieved in this 
system (Fig. 9A). Therefore, the amount of drug included in S-Cx(F+NP) was enough to provide an initial 
concentration with an antimicrobial effect. The drug release profile (Fig. 9B), showed an increased initial release 
compared to S-CxNP that was later followed by a slow release at later time points. The kinetic release profile of 
the drug from this system was also fitted to the same model as explained above, and the increase in the initial 
release by the incorporation of free drug was further confirmed by the lower value of the parameter δ (0.3 vs 0.48), 
which indicated a larger burst release. The results obtained indicated that these conditions allow a shock dose in 
the first hours and a sustained cephalexin release afterwards. 
A comparison among the different scaffolds of the cephalexin released percentage and the amount of 
cephalexin remaining in the system after 24 h is showed in figure 9C. Data included in this figure show a larger 
cephalexin released % for S-Cx(F+NP) compared to S-CxNP, and much lower than that of S-CxF. On the other 
hand, when the amount of drug remaining within the samples after 24 h of release was evaluated (Fig. 9C), it 
could be observed that while S-CxNP and S-Cx(F+NP) still had a significant amount of drug, S-CxF had 
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completely released all of its content, and would be incapable of providing any kind of sustained concentration of 
antibiotic. Therefore, the results obtained indicated that our synthetic scaffolds were able to release an antibiotic 
in a sustained manner to fight infection.
Finally, blood vessel formation has been identified as a fundamental step in bone regeneration [67,68]. 
Therefore, inducing angiogenesis appears as a promising strategy to enhance bone regeneration. Our versatile 
composite scaffolds were co-loaded with an angiogenesis-promoting protein, VEGF, to ease the colonization of 
the porous scaffolds by newly-formed blood vessels. These blood vessels would supply the nutrients needed for 
the formation of new bone, also enabling the correct disposal of waste products. Since our bone regeneration 
supports were fabricated at low temperature, a controlled amount of VEGF could be introduced during the 
fabrication scaffold process. The biological activity of VEGF released from our scaffolds was studied using an ex 
ovo chicken embryo CAM model. The ex ovo CAM model enables an easy evaluation of angiogenic response 
when exposed to different materials, and even allows carrying out several experiments in a single embryo. Since 
chick embryos sacrificed before hatching are not considered to be animals, the bureaucratic burden associated 
to their use is greatly reduced compared to animal studies. The CAM of chick embryos undergoes a rapid 
evolution between days 8 and 15 of embryonic development, which provides us with a window of several days to 
start any experiment trying to analyze pro- or anti-angiogenic strategies. Scaffolds containing nanoparticles, 
without and with VEGF (0.5 g/piece) [51–53], were placed on the CAM of chicken embryos on embryonic day 
ED-10 (Fig. 10). On ED-14, photographs of the surrounding vasculature were taken. The pictures (Fig. 10), 
showed a marked increase in the number of blood vessels (especially small capillaries) around the scaffold when 
VEGF was included in the scaffolds (Fig. 10 right, top). This positive result highlighted the great potential of this 
strategy, inducing the formation of new blood vessels to ensure nutrient support for the cells growing on it. 
Taking all of our results together, we have successfully designed and fabricated a multifunctional composite 
scaffold with 3D connected porosity. The obtained scaffolds containing SiO2 nanoparticles enabled the growth of 
bone cells on their surface. Different biologically active molecules, such us cephalexin and VEGF, were introduced 
simultaneously and homogeneously into the scaffold which composition resembles the extracellular matrix where 
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water constitutes the main component. Besides, this environment would constitute an outstanding surrounding 
that contributes to the preservation of biomolecules against enzymatic degradation and immunologic 
neutralization in vivo. All of these characteristics show the tremendous potential of the materials here presented 
for their future use in bone regeneration.
4. Conclusions
A composite scaffold with 3D connected porosity constituted by agarose, apatite and mesopororus silica 
nanoparticles was fabricated. These scaffolds could perform multiple functions simultaneously: i) the surface of 
the material was suitable for the adhesion of preosteoblast cells, which could grow on the scaffolds without any 
toxicity related to any of the components of our constructs, ii) the antibiotic cephalexin could be released from the 
material in a controlled manner thanks to the combination of free and nanoparticle-encapsulated drug, providing 
local concentrations capable of inhibiting bacterial growth, and iii) the release of co-loaded VEGF was also 
capable of inducing the formation of new blood vessels in the area, a key characteristic to facilitate bone 
regeneration.
While in this work we have employed a combination of non-encapsulated and encapsulated antibiotic as a 
means to obtain a sustained release system with enough initial inhibitory effect, future research could try to modify 
the surface of the nanoparticles to enable loading larger amounts of drug, or provide the system with release-
triggering mechanisms upon certain environmental changes.
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The localized delivery of bioactive molecules has attracted significant attention due to the potential for dose 
reduction as well as reduced side effects compared to systemic delivery. In this article multifunctional 3D porous 
scaffolds with a designed porosity have been fabricated. The method also enables the controlled loading of an 
antibiotic drug and an angiogenic protein into the scaffold. These scaffolds, whose composition resembles the 
extracellular matrix are suitable for the adhesion of preosteoblast cells, exhibit a sustained cephalexin delivery 
adequate for inhibiting bacterial growth as well as release the proangiogenic molecule which induces blood vessel 




Figure 1. Schematic representation of the fabrication method of 
multifunctional scaffolds for bone regeneration.
Figure 2. TEM micrographs of SiO2-nanoparticles (A) and N2 adsorption 
isotherms of nanoparticles without/with cephalexin (B).
Figure 3. Cephalexin released from nanoparticles versus time. The 
parameters of the kinetic fitting are shown on the curve.
Figure 4. Photograph corresponding to an agarose/nHCA scaffold 
containing SiO2-nanoparticles (A); SEM micrographs of these scaffolds at 
different magnifications (B and C).
Figure 5. SEM images and the corresponding EDS elemental analysis 
corresponding to agarose/nCHA scaffolds without (left) and with (right) 
silica nanoparticles.
Figure 6. Micrographs showing water drop profiles on different material 
surfaces. Contact angles were determined as indicated (A); MCT3T3-E1 
cell proliferation (measured by Alamar Blue assay) at day 3 of culture (B).
Figure 7. Cephalexin released from different scaffolds versus time. The 
parameters of the kinetic fitting are shown on the corresponding curves.
Figure 8. Agar disk diffusion test of the different materials prepared: 
agarose/nHCA with nanoparticles (S-NP), with free cephalexin (S-CxF) or 
with encapsulated cephalexin (SCxNP).
Figure 9. S-Cx(F+NP) scaffolds: Agar disk diffusion test (A); Cephalexin 
release versus time (B); A comparison among the different scaffolds of the 
cephalexin released percentage and the amount of cephalexin remaining in 
the system after 24 h (C).
Figure 10. Photograph of a chick embryo with two scaffolds placed on top 
of the CAM on day 10 of embryonic development (left) and 
stereomicroscope image of the effect of the scaffolds on surrounding 
vasculature at ED-14, either without VEGF (right, bottom) or with VEGF 
loaded in the scaffolds (right, top).
  
21
  
22
  
23
  
24
  
25
  
26
  
27
  
28
  
29
  
30
  
31
Graphical abstract
